|
| Monday, February 15, 2016 |
|
|
Eisai and Sysmex Enter Comprehensive Agreement to Create Next-Generation Diagnostic Reagents in the Field of Dementia |
| Eisai Co., Ltd. and Sysmex Corporation jointly announced that the two companies have entered into a comprehensive non-exclusive collaboration agreement aimed at the creation of new diagnostics in the field of dementia. more info >> |
|
| Friday, February 12, 2016 |
|
|
Phase III Trial Results of Eisai's Anticancer Agent Halaven(R) in Soft Tissue Sarcoma Published in The Lancet |
| Eisai Co., Ltd. announced today that the results of a Phase III clinical study (Study 309) of its in-house discovered and developed anticancer agent Halaven(R) (eribulin mesylate) in patients with locally advanced, recurrent or metastatic soft tissue sarcoma (liposarcoma or leiomyosarcoma)[1] have been published in the online version of The Lancet. more info >> |
|
| Monday, February 1, 2016 |
|
|
Eisai Acquires Exclusive License from Huya Bioscience International to Develop and Market HDAC Inhibitor HBI-8000 in Japan and Other Asian Countries |
| Eisai Co., Ltd. (TSE:4523) announced today that Eisai has entered into an exclusive license agreement with HUYA Bioscience International, LLC (San Diego, CA, USA) to develop and market the oral histone deacetylase (HDAC) inhibitor HBI-8000 in Japan, South Korea, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Singapore. more info >> |
|
| Tuesday, January 12, 2016 |
|
|
Eisai Submits New Application in Europe for In-House Developed Anticancer Agent Lenvatinib Seeking Approval for Indication Covering Renal Cell Carcinoma |
| Eisai Co., Ltd. announced today that its European regional headquarters Eisai Europe Ltd. (Location: U.K.) has submitted a new application to the European Medicines Agency (EMA) for its in-house developed novel anticancer agent lenvatinib mesylate for use in the treatment of advanced or metastatic renal cell carcinoma. more info >> |
|
| Friday, December 11, 2015 |
|
|
MHLW Approves Partial Label Change for Egg-White Lysozyme Preparation Neuzym |
| Eisai Co., Ltd. announced today that its partial label change application to remove chronic sinusitis as an approved indication for egg-white lysozyme preparation Neuzym has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW). more info >> |
|
| Tuesday, December 1, 2015 |
|
|
Eisai and Toyama Chemical Clear All-Case Surveillance Condition for Approval of Antirheumatic Agent Iguratimod |
Eisai Co., Ltd. and Fujifilm Group company Toyama Chemical Co., Ltd. announced today that they have received notification from Japan's Ministry of Health, Labour and Welfare (MHLW) to the effect that the "all-case surveillance" special drug use-results survey condition required for approval of the antirheumatic agent iguratimod has been lifted.
more info >> |
|
|
U.S. FDA Accepts NDA for Once-Daily Formulation of Antiobesity Agent Belviq |
| Eisai Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for a once-daily formulation of its antiobesity agent BELVIQ which has the potential to offer patients the convenience of once-daily treatment. more info >> |
|
| Tuesday, November 17, 2015 |
|
|
Successful Ruling in Patent Infringement Litigation for Antiemetic Agent Aloxi in the United States |
Eisai Co., Ltd. announced today that the U.S. District Court for the District of New Jersey has ruled in favor of Helsinn Healthcare S.A. in the patent infringement lawsuit for antiemetic agent ALOXI (palonosetron hydrochloride) brought by Helsinn together with Roche Palo Alto LLC (Roche) against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. in the United States, where it was determined that certain formulation patent claims for ALOXI are valid and infringed.
more info >> |
|
| Thursday, November 5, 2015 |
|
|
Eisai to Commence Two Joint Research Programs toward Development of New Antimalarial Medicines |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has entered into two joint research agreements for the development of new antimalarial medicines. more info >> |
|
| Monday, November 2, 2015 |
|
|
Eisai Presents Results from Phase III Trial of Antiepileptic Drug Perampanel as Adjunctive Therapy for Refractory Partial-Onset Seizures Conducted in Asia Including Japan Oral Presentation Given at 49th Congress of The Japan Epilepsy Society |
| Eisai Co., Ltd. announced today that an oral presentation highlighting results from a Phase III clinical study (Study 335) of its in-house developed antiepileptic drug (AED) perampanel hydrate (global product name: Fycompa) in patients with refractory partial-onset seizures conducted in Asia, including Japan, was given at the 49th Congress of the Japan Epilepsy Society held from October 30 to 31 in Nagasaki, Japan. more info >> |
|
|
|
